Well, I'm very glad we didn't put out any price sensitive...

Well, I'm very glad we didn't put out any price sensitive announcements today!!

We have held up reasonably well considering the wider market sell-off, and no one can guarantee that things might slip lower as full on panic sets in for some.

There will be some very happy cashed up investors looking to pick up some bargains over the next few weeks, so I would assume biotech companies not bringing in any income would be low on the wish list.

There is not any reason to sell out of Imugene, as we do have cash in the bank and will shortly be releasing some preliminary data from our OnCARlytics trial showing data from the combination cohort with Blincyto.

If this data confirms that the Oncolytic virus shuttles up the CD-19 protein on the cancer cell surface, and that the Blincyto inds the cancer then we are well on out way to the paradigm shift in cancer treatment that Leslie and Yuman have often alluded to.

What is not often acknowledged is that Imugene is not targeting the low hanging fruit in the cancer space, unlike many of our contemporaries that are seeking the easiest way to approvals through combination therapies that only marginally improve patient outcomes.

We would all love to have come in at this price point with the promise of incredible treatments about to be made available, within the next few years that is, however many have paid a premium as there would be many that got caught up in the excitment on the road to 62c.

Lets hope that 62c can come about again after further good news is provided from our 3 trials.

DYOR opinion only